The involvement of children in clinical trials of pharmaceuticals continues to be limited, especially in certain areas like the use of medication in newborns as well as long-term drug safety and effectiveness in children, according to an Institute of Medicine (IOM) report.
The IOM’s 29 February report offers recommendations on how Congress and the Food and Drug Administration (FDA) could further improve the usefulness of clinical information obtained from paediatric studies.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.